Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which ...
Eli Lilly expects its experimental weight loss pill, orforglipron, to receive approval as early as next year, CEO David Ricks told Bloomberg Jan. 13, according to a Wall Street Journal report.
Eli Lilly & Co. (LLY) thinks its next experimental weight-loss pill could get approved as soon as early 2026. CEO Dave Ricks told Bloomberg News on Monday that data on the drug, orforglipron ...
Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity ...
Eli Lilly expects ... trial data on the drug, orforglipron, by the middle of this year. Get top local stories in DFW delivered to you every morning. Sign up for NBC DFW's News Headlines newsletter.